Literature DB >> 22576029

Robotic totally endoscopic multivessel coronary artery bypass grafting: procedure development, challenges, results.

Johannes Bonatti1, Jeffrey D Lee, Nikolaos Bonaros, Thomas Schachner, Eric J Lehr.   

Abstract

Closed-chest totally endoscopic coronary artery bypass grafting (TECAB) is feasible using robotic technology. During the early phases, TECAB was restricted to single bypass grafts to the left anterior descending artery system. Because most patients referred for coronary artery bypass surgery have multivessel disease, development of endoscopic multiple bypass grafting is mandatory. Experimental work on multivessel TECAB was carried out in the early 2000s, and first clinical cases were already performed. With further technological development of operating robots, double, triple, and quadruple TECAB has become feasible both on the arrested heart and on the beating heart. To date, 161 cases of multivessel TECAB using the da Vinci telemanipulation systems are published in the literature. The main advances enabling multivessel TECAB were the availability of a robotic endostabilizer for beating heart procedures and increased surgeon skills using remote access heart-lung machine perfusion and endo-cardioplegia. Both internal mammary arteries can be harvested and both radial artery and vein graft can be used in multivessel TECAB. Y-grafting and sequential grafting are feasible. Multivessel endoscopic surgical revascularization can be combined with percutaneous coronary interventions in advanced hybrid coronary revascularization. Time requirements for multivessel TECAB are significant, and conversion rates to larger thoracic incisions are higher than those observed for single-vessel TECAB. Clinical short- and long-term outcomes, however, seem to meet the standards of open coronary bypass surgery through sternotomy. The main advantages of multivessel TECAB are a completely preserved sternum, use of double internal mammary artery even in risk groups, and a remarkably short recovery time.

Entities:  

Mesh:

Year:  2012        PMID: 22576029     DOI: 10.1097/IMI.0b013e3182552ea8

Source DB:  PubMed          Journal:  Innovations (Phila)        ISSN: 1556-9845


  7 in total

Review 1.  Robotically assisted totally endoscopic coronary artery bypass surgery.

Authors:  Leonardo Secchin Canale; Stephanie Mick; Tomislav Mihaljevic; Ravi Nair; Johannes Bonatti
Journal:  J Thorac Dis       Date:  2013-11       Impact factor: 2.895

2.  Robotic totally endoscopic coronary artery bypass grafting (TECAB) of the left anterior descending and right coronary artery system using an arterial Y-graft technique.

Authors:  Johannes Bonatti; Laszlo Göbölös; Jehad Ramahi; Thomas Bartel
Journal:  Ann Cardiothorac Surg       Date:  2018-09

Review 3.  Robotic totally endoscopic coronary artery bypass grafting (TECAB)-placement of bilateral internal mammary arteries to the left ventricle.

Authors:  Johannes Bonatti; Antti Vento; Nikolaos Bonaros; Mahmoud Traina; Eric Lehr
Journal:  Ann Cardiothorac Surg       Date:  2016-11

4.  Review of Contemporary Techniques for Minimally Invasive Coronary Revascularization.

Authors:  Ali Fatehi Hassanabad; Jimmy Kang; Andrew Maitland; Corey Adams; William D T Kent
Journal:  Innovations (Phila)       Date:  2021-06-03

Review 5.  Minimally invasive and robotic coronary artery bypass grafting-a 25-year review.

Authors:  Johannes Bonatti; Stephanie Wallner; Ingo Crailsheim; Martin Grabenwöger; Bernhard Winkler
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

Review 6.  Sutureless versus Hand-Sewn Coronary Anastomoses: A Systematic Review and Meta-Analysis.

Authors:  Marieke Hoogewerf; Jeroen Schuurkamp; Johannes C Kelder; Stephan Jacobs; Pieter A Doevendans
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

Review 7.  Revascularization strategies for patients with established chronic coronary syndrome.

Authors:  Casper F Coerkamp; Marieke Hoogewerf; Bart P van Putte; Yolande Appelman; Pieter A Doevendans
Journal:  Eur J Clin Invest       Date:  2022-04-29       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.